Vertex: The Quiet Biotech Compounder I’d Happily Hold Through Any Market Crash
Vertex Pharmaceuticals stands out as a resilient biotech powerhouse with dominant cystic fibrosis therapies driving consistent revenue, emerging diversification through gene editing with Casgevy, non-opioid pain treatment Journavx, and a robust pipeline in renal diseases and beyond—positioning it for sustained compounding growth even in volatile markets, with shares recently trading around $491 amid analyst upgrades … Read more